184 related articles for article (PubMed ID: 36329085)
1. Discovering cell-active BCL6 inhibitors: effectively combining biochemical HTS with multiple biophysical techniques, X-ray crystallography and cell-based assays.
Pierrat OA; Liu M; Collie GW; Shetty K; Rodrigues MJ; Le Bihan YV; Gunnell EA; McAndrew PC; Stubbs M; Rowlands MG; Yahya N; Shehu E; Talbot R; Pickard L; Bellenie BR; Cheung KJ; Drouin L; Innocenti P; Woodward H; Davis OA; Lloyd MG; Varela A; Huckvale R; Broccatelli F; Carter M; Galiwango D; Hayes A; Raynaud FI; Bryant C; Whittaker S; Rossanese OW; Hoelder S; Burke R; van Montfort RLM
Sci Rep; 2022 Nov; 12(1):18633. PubMed ID: 36329085
[TBL] [Abstract][Full Text] [Related]
2. Identification of Thiourea-Based Inhibitors of the B-Cell Lymphoma 6 BTB Domain via NMR-Based Fragment Screening and Computer-Aided Drug Design.
Cheng H; Linhares BM; Yu W; Cardenas MG; Ai Y; Jiang W; Winkler A; Cohen S; Melnick A; MacKerell A; Cierpicki T; Xue F
J Med Chem; 2018 Sep; 61(17):7573-7588. PubMed ID: 29969259
[TBL] [Abstract][Full Text] [Related]
3. Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma.
Cardenas MG; Yu W; Beguelin W; Teater MR; Geng H; Goldstein RL; Oswald E; Hatzi K; Yang SN; Cohen J; Shaknovich R; Vanommeslaeghe K; Cheng H; Liang D; Cho HJ; Abbott J; Tam W; Du W; Leonard JP; Elemento O; Cerchietti L; Cierpicki T; Xue F; MacKerell AD; Melnick AM
J Clin Invest; 2016 Sep; 126(9):3351-62. PubMed ID: 27482887
[TBL] [Abstract][Full Text] [Related]
4. Discovery of an Irreversible and Cell-Active BCL6 Inhibitor Selectively Targeting Cys53 Located at the Protein-Protein Interaction Interface.
Sameshima T; Yamamoto T; Sano O; Sogabe S; Igaki S; Sakamoto K; Ida K; Gotou M; Imaeda Y; Sakamoto J; Miyahisa I
Biochemistry; 2018 Feb; 57(8):1369-1379. PubMed ID: 29293322
[TBL] [Abstract][Full Text] [Related]
5. Progress toward B-Cell Lymphoma 6 BTB Domain Inhibitors for the Treatment of Diffuse Large B-Cell Lymphoma and Beyond.
Ai Y; Hwang L; MacKerell AD; Melnick A; Xue F
J Med Chem; 2021 Apr; 64(8):4333-4358. PubMed ID: 33844535
[TBL] [Abstract][Full Text] [Related]
6. Discovery of a B-Cell Lymphoma 6 Protein-Protein Interaction Inhibitor by a Biophysics-Driven Fragment-Based Approach.
Kamada Y; Sakai N; Sogabe S; Ida K; Oki H; Sakamoto K; Lane W; Snell G; Iida M; Imaeda Y; Sakamoto J; Matsui J
J Med Chem; 2017 May; 60(10):4358-4368. PubMed ID: 28471657
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a novel B-cell lymphoma 6 (BCL6)-corepressor interaction inhibitor by utilizing structure-based drug design.
Yasui T; Yamamoto T; Sakai N; Asano K; Takai T; Yoshitomi Y; Davis M; Takagi T; Sakamoto K; Sogabe S; Kamada Y; Lane W; Snell G; Iwata M; Goto M; Inooka H; Sakamoto JI; Nakada Y; Imaeda Y
Bioorg Med Chem; 2017 Sep; 25(17):4876-4886. PubMed ID: 28760529
[TBL] [Abstract][Full Text] [Related]
8. Discovery of Pyrazolo[1,5-a]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic Inhibitors.
McCoull W; Abrams RD; Anderson E; Blades K; Barton P; Box M; Burgess J; Byth K; Cao Q; Chuaqui C; Carbajo RJ; Cheung T; Code E; Ferguson AD; Fillery S; Fuller NO; Gangl E; Gao N; Grist M; Hargreaves D; Howard MR; Hu J; Kemmitt PD; Nelson JE; O'Connell N; Prince DB; Raubo P; Rawlins PB; Robb GR; Shi J; Waring MJ; Whittaker D; Wylot M; Zhu X
J Med Chem; 2017 May; 60(10):4386-4402. PubMed ID: 28485934
[TBL] [Abstract][Full Text] [Related]
9. Clinical Significance of
Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
[No Abstract] [Full Text] [Related]
10. An orally available small molecule BCL6 inhibitor effectively suppresses diffuse large B cell lymphoma cells growth in vitro and in vivo.
Xing Y; Guo W; Wu M; Xie J; Huang D; Hu P; Zhou M; Zhang L; Zhang Q; Wang P; Wang X; Wang G; Wu H; Zhou C; Chen Y; Liu M; Yi Z; Sun Z
Cancer Lett; 2022 Mar; 529():100-111. PubMed ID: 34990752
[TBL] [Abstract][Full Text] [Related]
11. MEF2B is a member of the BCL6 gene transcriptional complex and induces its expression in diffuse large B-cell lymphoma of the germinal center B-cell-like type.
El Jamal SM; Grada Z; El Dinali MH; Zhou H; Hassan SY; Saad AG; Gibson B; Zhou X; Abulsayen HA; Khadra HS; Friedman J; Shalaby H; Kadi A; Megahed M; Emberesh M; Teruya-Feldstein J; Firpo-Betancourt A; Haikel Y; Fraig M; Hassan M
Lab Invest; 2019 Apr; 99(4):539-550. PubMed ID: 30446717
[TBL] [Abstract][Full Text] [Related]
12. A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo.
Cerchietti LC; Ghetu AF; Zhu X; Da Silva GF; Zhong S; Matthews M; Bunting KL; Polo JM; Farès C; Arrowsmith CH; Yang SN; Garcia M; Coop A; Mackerell AD; Privé GG; Melnick A
Cancer Cell; 2010 Apr; 17(4):400-11. PubMed ID: 20385364
[TBL] [Abstract][Full Text] [Related]
13. Analysis of primary central nervous system large B-cell lymphoma in the era of high-grade B-cell lymphoma: Detection of two cases with MYC and BCL6 rearrangements in a cohort of 12 cases.
Pina-Oviedo S; Bellamy WT; Gokden M
Ann Diagn Pathol; 2020 Oct; 48():151610. PubMed ID: 32889391
[TBL] [Abstract][Full Text] [Related]
14. BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms.
Parekh S; Polo JM; Shaknovich R; Juszczynski P; Lev P; Ranuncolo SM; Yin Y; Klein U; Cattoretti G; Dalla Favera R; Shipp MA; Melnick A
Blood; 2007 Sep; 110(6):2067-74. PubMed ID: 17545502
[TBL] [Abstract][Full Text] [Related]
15. The Expanding Role of the BCL6 Oncoprotein as a Cancer Therapeutic Target.
Cardenas MG; Oswald E; Yu W; Xue F; MacKerell AD; Melnick AM
Clin Cancer Res; 2017 Feb; 23(4):885-893. PubMed ID: 27881582
[TBL] [Abstract][Full Text] [Related]
16. Synergistic activity of Card11 mutant and Bcl6 in the development of diffuse large B-cell lymphoma in a mouse model.
Takahara T; Matsuo K; Seto M; Nakamura S; Tsuzuki S
Cancer Sci; 2016 Nov; 107(11):1572-1580. PubMed ID: 27560392
[TBL] [Abstract][Full Text] [Related]
17. MYC/BCL6 double-hit lymphoma (DHL): a tumour associated with an aggressive clinical course and poor prognosis.
Li S; Desai P; Lin P; Yin CC; Tang G; Wang XJ; Konoplev SN; Khoury JD; Bueso-Ramos CE; Medeiros LJ
Histopathology; 2016 Jun; 68(7):1090-8. PubMed ID: 26426741
[TBL] [Abstract][Full Text] [Related]
18. EBV
Liu H; Xu-Monette ZY; Tang G; Wang W; Kim Y; Yuan J; Li Y; Chen W; Li Y; Fedoriw GY; Zhu F; Fang X; Luedke C; Medeiros LJ; Young KH; Hu S
Histopathology; 2022 Feb; 80(3):575-588. PubMed ID: 34637146
[TBL] [Abstract][Full Text] [Related]
19. Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6.
McCoull W; Cheung T; Anderson E; Barton P; Burgess J; Byth K; Cao Q; Castaldi MP; Chen H; Chiarparin E; Carbajo RJ; Code E; Cowan S; Davey PR; Ferguson AD; Fillery S; Fuller NO; Gao N; Hargreaves D; Howard MR; Hu J; Kawatkar A; Kemmitt PD; Leo E; Molina DM; O'Connell N; Petteruti P; Rasmusson T; Raubo P; Rawlins PB; Ricchiuto P; Robb GR; Schenone M; Waring MJ; Zinda M; Fawell S; Wilson DM
ACS Chem Biol; 2018 Nov; 13(11):3131-3141. PubMed ID: 30335946
[TBL] [Abstract][Full Text] [Related]
20. BCL6 suppression of BCL2 via Miz1 and its disruption in diffuse large B cell lymphoma.
Saito M; Novak U; Piovan E; Basso K; Sumazin P; Schneider C; Crespo M; Shen Q; Bhagat G; Califano A; Chadburn A; Pasqualucci L; Dalla-Favera R
Proc Natl Acad Sci U S A; 2009 Jul; 106(27):11294-9. PubMed ID: 19549844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
